Literature DB >> 8490839

Primary carcinoma of the female urethra. Results of radiation therapy.

A S Garden1, G K Zagars, L Delclos.   

Abstract

BACKGROUND: This retrospective study analyzed treatment outcomes, patterns of failure, and complications of treating nonmetastatic primary carcinomas of the female urethra with radiation therapy.
METHODS: Ninety-seven women with this uncommon malignancy were treated with radiation therapy at the University of Texas M.D. Anderson Cancer Center between 1955-1989. Eighty-six patients received radiation only after excision or biopsy of their primary lesions: 35 were treated with a combination of external beam irradiation and brachytherapy, 21 with external beam irradiation only, and 30 with brachytherapy only. The cumulative doses ranged from 40-106 Gy (median, 65 Gy). The other 11 women received radiation therapy preoperatively. The median follow-up for surviving patients was 105 months (range, 20-337 months).
RESULTS: Five-year, 10-year, and 15-year actuarial survival rates were 41%, 31%, and 22%, respectively. Extension of the primary tumor into adjacent structures, involvement of the entire urethral length, and fixation of the primary lesion were all associated with poorer survival (P < 0.05). The 1-year, 2-year, and 5-year local control rates in 84 evaluable patients who received radiation only were 72%, 65%, and 64%, respectively. Only involvement of the entire urethra predicted poorer local control. Twenty-seven of 55 patients (49%) who achieved local control had complications, including urethral stenosis (n = 11), fistula or necrosis (n = 10), and cystitis and/or hemorrhage (n = 6). The complications were considered mild in 5 patients, moderate in 14, and severe in 8. Higher doses correlated with a greater incidence of complications but not with improved local control. There was a trend of fewer complications in more recent years.
CONCLUSIONS: Primary carcinoma of the female urethra is curable with radiation therapy, although the complication rates are significant. Current knowledge of normal tissue tolerance and improved brachytherapy techniques may help minimize the complications.

Entities:  

Mesh:

Year:  1993        PMID: 8490839     DOI: 10.1002/1097-0142(19930515)71:10<3102::aid-cncr2820711034>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Successful management of female urethral carcinoma with radiation therapy and concurrent chemotherapy.

Authors:  William J Magnuson; Kristin Bradley; Mark Shaves
Journal:  Gynecol Oncol Case Rep       Date:  2011-11-04

Review 2.  Current Perspectives on the Diagnosis and Management of Primary Urethral Cancer: A Systematic Review.

Authors:  M Ryan Farrell; Jonathan T Xu; Alex J Vanni
Journal:  Res Rep Urol       Date:  2021-06-01

3.  Palladium interstitial implant in combination with external beam radiotherapy and chemotherapy for the definitive treatment of a female urethral carcinoma.

Authors:  Hilary P Bagshaw; Ned L Williams; Y Jessica Huang; Jonathan D Tward; David K Gaffney
Journal:  Gynecol Oncol Rep       Date:  2015-06-10

4.  Skene duct adenocarcinoma in a patient with an elevated serum prostate-specific antigen level: a case report.

Authors:  Sohgo Tsutsumi; Takashi Kawahara; Yusuke Hattori; Taku Mochizuki; Jun-Ichi Teranishi; Kazuhide Makiyama; Yasuhide Miyoshi; Masako Otani; Hiroji Uemura
Journal:  J Med Case Rep       Date:  2018-02-14

5.  External Urethral Orifice Metastasis of Cervical Cancer Treated With Intraluminal Urethral Brachytherapy Using a Lumencath Applicator: The First Case Report.

Authors:  Yoshiaki Takagawa; Sachiko Izumi; Tomoyuki Okano; Eiichi Takahashi; Yuki Wakamatsu; Megumi Takahara; Haruka Okada; Midori Kita
Journal:  Adv Radiat Oncol       Date:  2021-10-06

6.  Survival Outcomes and Predictive Factors for Female Urethral Cancer: Long-term Experience with Korean Patients.

Authors:  Minyong Kang; Chang Wook Jeong; Cheol Kwak; Hyeon Hoe Kim; Ja Hyeon Ku
Journal:  J Korean Med Sci       Date:  2015-07-15       Impact factor: 2.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.